PT-141 (Bremelanotide) Medicare Advantage Coverage

Why Medicare Advantage Plans Exclude PT-141

Medicare Advantage (MA) plans must follow the same statutory drug coverage rules as Original Medicare Part D. Under the Social Security Act Section 1860D-2(e)(2)(A), drugs used for sexual or erectile dysfunction are explicitly excluded from Part D coverage [3]. This exclusion applies regardless of the prescribing indication, and it covers bremelanotide (Vyleesi) by default because the FDA label specifies hypoactive sexual desire disorder (HSDD) as the approved use.

This is not a formulary decision that individual plans can override. Even MA-PD plans (Medicare Advantage plans with integrated Part D) cannot add Vyleesi to their formularies. The Congressional Budget Office estimated in 2020 that removing Part D exclusions for sexual dysfunction drugs would cost $4.3 billion over 10 years [4], and no legislative change has passed as of May 2026. Some advocacy groups, including the International Society for the Study of Women's Sexual Health (ISSWSH), have argued that excluding female sexual dysfunction treatments from Medicare represents a gender-based disparity in coverage, since conditions like HSDD affect an estimated 10% of women across all age groups [5].

A small number of Medicare Advantage plans in 2026 offer supplemental benefits under the "Special Supplemental Benefits for the Chronically Ill" (SSBCI) framework, which CMS expanded in 2020. These benefits occasionally include wellness or sexual health services, but they almost never extend to prescription drug coverage for excluded categories. Check your specific plan's Evidence of Coverage document for the most current details.

What Vyleesi Actually Costs Without Insurance

The retail cash price for branded Vyleesi is approximately $1,200 for a single-use, prefilled autoinjector containing 1.75 mg of bremelanotide. Patients who use the medication twice monthly face annual costs exceeding $28,000. That price point has limited commercial uptake considerably. Palatin Technologies reported peak U.S. net revenue of only $4.2 million for Vyleesi in 2021, a figure that reflects both narrow insurance coverage in the commercial market and high out-of-pocket burden [6].

Pharmacy benefit managers (PBMs) that do cover Vyleesi on commercial plans typically place it on Tier 4 or Tier 5 (specialty tier), with copays ranging from $150 to $400 per fill even for insured patients. For Medicare Advantage enrollees who lack any coverage pathway for this drug, the full retail price applies.

GoodRx and similar discount platforms occasionally list Vyleesi at $900 to $1,100 per autoinjector, but availability fluctuates. The branded product requires no reconstitution and delivers a fixed 1.75 mg subcutaneous dose, which some patients prefer for convenience despite the cost premium.

Compounded Bremelanotide: The $140 Alternative

Compounded bremelanotide from FDA-registered 503B outsourcing facilities represents the most cost-effective access route for Medicare Advantage enrollees. Average monthly costs for compounded subcutaneous bremelanotide run approximately $140, a fraction of the branded Vyleesi price.

Compounding pharmacies prepare bremelanotide as a multi-use vial requiring reconstitution and self-injection with insulin syringes. A typical compounded vial contains 10 mg of bremelanotide, providing approximately five to six 1.75 mg doses. The per-dose cost drops to roughly $25 to $35 compared with $1,200 for the branded autoinjector.

The FDA distinguishes between 503A (patient-specific) and 503B (outsourcing facility) compounding. For bremelanotide, 503B facilities can produce larger batches under current Good Manufacturing Practice (cGMP) conditions, which improves consistency and allows direct distribution to prescribers or patients [7]. When selecting a compounding pharmacy, confirm that the facility holds FDA 503B registration and state licensure. The FDA maintains a searchable database of registered outsourcing facilities at accessdata.fda.gov.

Compounded bremelanotide is not FDA-approved in the same sense as Vyleesi. It contains the same active pharmaceutical ingredient but has not undergone the identical regulatory review process for the specific compounded formulation. Prescribers should counsel patients on this distinction.

How the RECONNECT Trials Support Bremelanotide Use

The FDA approved Vyleesi based on two identical Phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT 1 and RECONNECT 2 (N=1,247 total). In these trials, premenopausal women with generalized acquired HSDD self-administered bremelanotide 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity [2].

Results showed that 25.4% of bremelanotide-treated patients achieved a clinically meaningful increase of 1.2 or more points on the Female Sexual Function Index (FSFI) desire domain, compared with 17.0% on placebo. On the co-primary endpoint, the Female Sexual Distress Scale (FSDS-DAO) Item 13, 34.9% of bremelanotide patients reported meaningful reductions in distress versus 27.3% on placebo [8].

"Bremelanotide demonstrated a statistically significant improvement in sexual desire and a reduction in distress associated with low desire compared to placebo," noted the FDA's Clinical Review for NDA 210557 [1]. The treatment effect, while modest in absolute terms, was consistent across both trials and maintained through the 24-week treatment period.

Nausea was the most common adverse event, affecting 40.2% of bremelanotide patients versus 1.3% on placebo. About 13% of patients in the bremelanotide group received an antiemetic. Nausea typically decreased with repeated dosing. The prescribing information carries a warning about transient blood pressure increases (mean systolic rise of 2 to 3 mmHg), and bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].

Step-by-Step: Getting PT-141 as a Medicare Advantage Enrollee

Since standard formulary coverage is unavailable, Medicare Advantage members need an alternative access pathway. Here is a practical sequence.

Step 1: Confirm your diagnosis. HSDD requires both persistently low sexual desire causing personal distress and the absence of another medical, psychiatric, or relationship-based explanation. The Decreased Sexual Desire Screener (DSDS) is a validated 5-item tool clinicians use to differentiate HSDD from other causes [9].

Step 2: Get a prescription from a licensed provider. Bremelanotide requires a prescription. Telehealth platforms, including HealthRX, connect patients with licensed clinicians who can evaluate HSDD and prescribe compounded bremelanotide where clinically appropriate.

Step 3: Choose a compounding pharmacy. Select an FDA-registered 503B outsourcing facility. Confirm state licensure and ask about third-party potency and sterility testing. Expect to pay $120 to $160 per month for compounded bremelanotide.

Step 4: Learn proper injection technique. Compounded bremelanotide is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Subcutaneous injection into the abdomen or thigh using a 29- or 30-gauge insulin syringe is standard. Your provider or pharmacist should demonstrate reconstitution and injection technique.

Step 5: Track your response. The Endocrine Society and ISSWSH recommend reassessing HSDD treatment response at 8 to 12 weeks [10]. If desire and distress scores have not improved, dose adjustments or alternative therapies may be warranted.

Other Ways to Reduce PT-141 Costs

Beyond compounding, several strategies can lower the cost of bremelanotide for Medicare Advantage enrollees and uninsured patients.

Manufacturer savings programs. Palatin Technologies and its commercial partners have periodically offered copay cards and savings programs for commercially insured patients. These programs do not apply to Medicare beneficiaries under the Anti-Kickback Statute, but patients with Medigap or secondary commercial coverage should verify eligibility directly with the manufacturer's patient support line.

Patient assistance programs (PAPs). Some pharmaceutical manufacturers offer free or reduced-cost medication to patients who meet income thresholds (typically at or below 300% of the Federal Poverty Level). Availability for Vyleesi specifically has been inconsistent. NeedyMeds and RxAssist maintain updated databases of PAPs.

Health Savings Account (HSA) or Flexible Spending Account (FSA) funds. Medicare Advantage enrollees who maintained an HSA from prior high-deductible health plan enrollment can use remaining HSA balances for qualified medical expenses, including prescription medications not covered by their plan. Bremelanotide prescribed for a diagnosed medical condition qualifies as an eligible expense.

Clinical trials. ClinicalTrials.gov lists active studies involving melanocortin receptor agonists. Enrollment in a trial may provide access to bremelanotide or next-generation compounds at no cost while contributing to the evidence base.

Telehealth-based compounding platforms. Services like HealthRX bundle the clinical consultation and pharmacy fulfillment into a single workflow, often at lower total cost than obtaining a separate office visit and pharmacy fill. Typical all-in monthly costs through these platforms range from $99 to $179.

Off-Label Considerations and Male Use of PT-141

While Vyleesi carries an FDA-approved indication only for premenopausal women with HSDD, bremelanotide has been studied in men with erectile dysfunction (ED). A Phase 2b trial (N=289) of intranasal bremelanotide in men with ED showed dose-dependent improvements in the International Index of Erectile Function (IIEF) score, though the intranasal formulation was not advanced to Phase 3 due to blood pressure concerns with that delivery route [11].

Subcutaneous bremelanotide is prescribed off-label by some clinicians for male sexual dysfunction, particularly in men who do not respond to phosphodiesterase-5 (PDE5) inhibitors like sildenafil or tadalafil, or who cannot take them due to nitrate use. Off-label prescribing is legal and common in medicine, but Medicare Advantage plans will not cover bremelanotide for any indication given the statutory exclusion.

The American Urological Association (AUA) does not include bremelanotide in its current ED guidelines, and prescribers should document clinical rationale when prescribing off-label [12]. Compounded bremelanotide for male patients follows the same pharmacy and cost pathways described above.

How PT-141 Compares to Other HSDD Treatments

Two FDA-approved treatments exist for HSDD: bremelanotide (Vyleesi) and flibanserin (Addyi). They work through different mechanisms and have distinct dosing profiles.

Flibanserin is a daily oral medication that acts on serotonin receptors (5-HT1A agonist / 5-HT2A antagonist). It requires 8 weeks of continuous daily use before efficacy can be assessed. The VIOLET trial (N=1,087) showed a mean increase of 0.5 satisfying sexual events per month over placebo [13]. Flibanserin carries an FDA boxed warning about hypotension and syncope with concurrent alcohol use, and it requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program.

Bremelanotide is used on-demand (as needed), does not require daily dosing, and has no alcohol interaction. The on-demand model appeals to patients who prefer not to take a daily medication for episodic symptoms. The main tradeoff is the injection route and the high nausea rate.

Neither drug is covered under Medicare Part D. Flibanserin is available as a generic (approved 2022) at approximately $30 to $80 per month, making it the lower-cost FDA-approved option for patients who tolerate daily oral dosing. For patients who need on-demand therapy or who failed flibanserin, compounded bremelanotide at $140 per month remains the most accessible alternative.

Checking Your Specific Medicare Advantage Plan

Even though the Part D statutory exclusion is clear, Medicare Advantage plans differ in their supplemental benefit packages. To verify your specific coverage:

1. Call the number on the back of your MA plan card and ask whether "bremelanotide or Vyleesi" appears on any supplemental benefit formulary.
2. Log into your plan's member portal and search the formulary tool. Most plans publish searchable formularies on their websites.
3. Request a coverage determination. Under 42 CFR 423.566, you have the right to request a formal coverage determination from your Part D plan [14]. If denied, you can appeal through the five-level Medicare appeals process, though success is unlikely for a statutory exclusion.
4. Ask about the SSBCI program. If your plan offers Special Supplemental Benefits for the Chronically Ill, ask whether sexual health services are included and whether they extend to prescription coverage.

Programs change frequently. What a plan excludes in plan year 2026 could shift in 2027 if CMS modifies supplemental benefit rules or if Congress amends the Part D exclusion list. Always verify directly with your plan.